Etubics is a biopharmaceutical company developing targeted immunotherapies and vaccine products for a range of resilient diseases. The company offers next-generation viral vector gene delivery technology and manufacturing cell line, together known as the Etubics Platform. It delivers an “active” immune response against diseases and induces both cell-mediated immunity and antibody.